摘要
目的探讨新型膜性雌激素受体ERα36在他莫昔芬(tamoxifen,TAM)治疗卵巢癌中的作用。方法转染特异性的siRNA,下调卵巢癌细胞SKOV3、HO8910中ERα36的表达;TAM处理肿瘤细胞后,采用CCK-8、流式细胞术及Western blot等方法检测卵巢癌细胞的增殖、凋亡及相关信号通路关键蛋白的表达。结果siRNA特异性下调ERα36蛋白的表达;CCK-8检测显示,1μmol/L TAM作用于卵巢癌细胞的抑制率较为适中,故作为后续实验的处理浓度;不同浓度的TAM作用ERα36下调的肿瘤细胞后,与siRNA对照组相比,肿瘤细胞抑制率明显上升(P<0.01);下调ERα36表达后,p-Akt蛋白表达显著下降(P<0.01),凋亡相关Caspase-3、Bax蛋白表达量显著升高(P<0.01),BCL-2蛋白表达显著降低(P<0.01)。结论利用特异性siRNA下调ERα36的表达后,可以增强TAM对卵巢癌细胞作用的敏感性。
Purpose To explore a new membranous estrogen receptor(ERα36)in the role of tamoxifen(TAM)treatment of ovarian cancer.Methods Transfection of siRNAs in ovarian cancer cell lines of SKOV3 and HO8910 was conducted to knock down the expression of ERα36.Then,to check proliferation ability,apoptotic rates and the expression of related signaling pathway key proteins after TAM treatment in ovarian cancer cells,by CCK-8 assay,flow cytometry and Western blot.Results siRNA could knock down specifically the expression of ERα36.CCK-8 assay showed that the inhibitory rate of 1μmol/L TAM on ovarian cancer cells was suitable,so it was used as the concentration for further experiments.After treatments with different concentrations of TAM,tumor cell inhibitory rates increased significantly(P<0.01).P-Akt expression was significantly decreased(P<0.01)and the expression of Caspase-3,Bax significantly increased(P<0.01).The BCL-2 expression significantly reduced(P<0.01)in ERα36 knock down group,compared with siRNA control group.Conclusion After the expression of ERα36 is down-regulated by specific siRNA,the sensitivity of TAM treatment in ovarian cancer cells could be enhanced.
作者
杨腾
王衡
刘斌
高胜兰
王亚红
黄剑
YANG Teng;WANG Heng;LIU Bin;GAO Sheng-lan;WANG Ya-hong;HUANG Jian(Pathological Diagnosis and Research Center,Affiliated Hospital of Guangdong Medical University,Zhanjiang 524001,China)
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2019年第11期1268-1274,共7页
Chinese Journal of Clinical and Experimental Pathology
基金
国家自然科学基金(81572610)
广东省“扬帆计划”引进紧缺拔尖人才(4YF16002G)
广东医科大学基金(M2017001、GDMUM201822)
